新型冠状病毒自然感染病例和免疫突破病例及新型冠状病毒灭活疫苗免疫人群特异性IgG抗体的动态变化特征  

Kinetics of SARS-CoV-2-specific antibodies among inactivated COVID-19 vaccine recipients,SARS-CoV-2 natural infection cases,and breakthrough cases

作　　者：金来润 李楚楚 陈聪[3] 王寅 王艳 何敏[6] 丁松宁[7] 魏明伟[2] 田华[2] 孔筱筱 董晨[2] 周璐[2] 彭杰夫 汪志国[2] 朱凤才[2] 朱立国[1,2] Jin Lairun;Li Chuchu;Chen Cong;Wang Yin;Wang Yan;He Min;Ding Songning;Wei Mingwei;Tian Hua;Kong Xiaoxiao;Dong Chen;Zhou Lu;Peng Jiefu;Wang Zhiguo;Zhu Fengcai;Zhu Liguo(School of Public Health,Southeast University,Nanjing 210009,China;Institute of Acute Infectious Disease Control,Jiangsu Provincial Center for Disease Control and Prevention,Nanjing 210009,China;Institute of Acute Infectious Disease Control,Changzhou Municipal Center for Disease Control and Prevention,Changzhou 213000,China;Institute of Acute Infectious Disease Control,Yangzhou Municipal Center for Disease Control and Prevention,Yangzhou 225000,China;Laboratory Department,Yangzhou Municipal Center for Disease Control and Prevention,Yangzhou 225000,China;Laboratory Department,Nanjing Municipal Center for Disease Control and Prevention,Nanjing 210003,China;Institute of Acute Infectious Disease Control,Nanjing Municipal Center for Disease Control and Prevention,Nanjing 210003,China)

机构地区：[1]东南大学公共卫生学院,南京210009 [2]江苏省疾病预防控制中心急性传染病防制所,南京210009 [3]常州市疾病预防控制中心急性传染病防制科,常州213000 [4]扬州市疾病预防控制中心急性传染病防制科,扬州225000 [5]扬州市疾病预防控制中心检验科,扬州225000 [6]南京市疾病预防控制中心微生物检验科,南京210003 [7]南京市疾病预防控制中心急性传染病防制科,南京210003

出　　处：《中华预防医学杂志》2022年第12期1834-1837,共4页Chinese Journal of Preventive Medicine

基　　金：江苏省社会发展项目(BE2021739)。

摘　　要：选取2021年8—9月南京和扬州市新型冠状病毒肺炎(新冠肺炎)疫情中的新冠肺炎病例和免疫突破病例,以及常州市新型冠状病毒灭活疫苗免疫人群为研究对象,分别纳入605例新冠病毒自然感染病例、589名免疫突破病例和690例新冠灭活疫苗免疫者。新冠病毒自然感染病例年龄为19~91岁,年龄M为66岁;IgG抗体水平在感染后第1~7周的M(Q1,Q3)依次为0.19(0.06~1.31)、3.70(0.76~69.48)、15.31(2.59~82.16)、4.41(0.99~31.74)、2.31(0.75~13.83)、2.28(0.68~9.94)、2.80(1.00~9.53)。免疫突破病例年龄为18~76岁,年龄M为45岁;IgG抗体水平在感染后第1~7周M(Q1,Q3)依次为1.93(0.34~26.67)、38.87(7.90~121.0)、75.09(11.85~123.70)、21.97(5.20~95.58)、13.97(3.47~46.82)、9.56(2.48~33.38)、4.38(1.87~11.00)。新型冠状病毒灭活疫苗免疫者年龄为18~87岁,年龄M为47岁;IgG抗体M(Q1,Q3)在疫苗接种后第1~8个月依次为16.22(15.84~33.42)、5.35(2.96~13.23)、3.30(2.18~6.18)、3.14(1.16~5.70)、2.77(1.50~4.52)、2.72(1.76~4.36)、2.01(1.27~3.51)、1.94(1.35~3.09)。结果提示,新型冠状病毒自然感染病例IgG抗体水平在新冠病毒自然感染后2周内逐渐上升,3~7周后逐渐下降;免疫突破病例IgG抗体在突破感染后2周内快速上升,3~7周后逐渐下降;新型冠状病毒灭活疫苗免疫人群IgG抗体水平在疫苗接种后3个月内快速下降,3个月后缓慢下降,保持在较低水平。Between August and September,2021,this study included 605 SARS-CoV-2 natural infection cases and 589 SARS-CoV-2 breakthrough cases from Nanjing and Yangzhou,as well as 690 inactivated COVID-19 vaccine recipients from Changzhou,China.In SARS-CoV-2 natural infection cases,the age range was 19-91 years(median age:66 year),and the medians(Q1,Q3)of IgG titers were 0.19(0.06-1.31),3.70(0.76-69.48),15.31(2.59-82.16),4.41(0.99-31.74),2.31(0.75-13.83),2.28(0.68-9.94)and 2.80(1.00-9.53)at one to seven weeks after SARS-CoV-2 infection,respectively.In SARS-CoV-2 breakthrough cases,the age range was 18-76 years(median age:45 year),and the medians(Q1,Q3)of IgG titers were 1.93(0.34-26.67),38.87(7.90-121.0),75.09(11.85-123.70),21.97(5.20-95.58),13.97(3.47-46.82),9.56(2.48-33.38)and 4.38(1.87-11.00)at one to seven weeks after SARS-CoV-2 infection,respectively.In inactivated COVID-19 vaccine recipients,the age range was 18-87 years(median age:47 years),and the medians(Q1,Q3)of IgG titers were 16.22(15.84-33.42),5.35(2.96-13.23),3.30(2.18-6.18),3.14(1.16-5.70),2.77(1.50-4.52),2.72(1.76-4.36),2.01(1.27-3.51)and 1.94(1.35-3.09)at one to eight months after SARS-CoV-2 infection,respectively.The results suggested that IgG antibodies increased gradually within two weeks after SARS-CoV-2 infection,then declined gradually at three to seven weeks in SARS-CoV-2 natural infection cases.In SARS-CoV-2 breakthrough cases,IgG antibodies increased rapidly within two weeks,then declined gradually at three to seven weeks after SARS-CoV-2 infection.Additionally,IgG antibodies decreased rapidly within three months,then decreased gradually and remained at a low level within three months after immunization.

关 键 词：新型冠状病毒肺炎 抗体 疫苗 免疫突破病例 纵向研究 

分 类 号：R186[医药卫生—流行病学]